TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05707572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual manipulation
Description: The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
Study: NCT02490163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
Study: NCT04684199

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
Study: NCT03878654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid
Description: Naturally occurirng bile acid
Study: NCT04100486

Intervention type: OTHER
Intervention: Standing-Squatting-Standing Test
Description: The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.

Intervention type: OTHER
Intervention: Deep Breathing Test
Description: The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.

Intervention type: OTHER
Intervention: Cold Pressor Test
Description: The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.

Intervention type: OTHER
Intervention: Cold Face Test
Description: The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.

Intervention type: OTHER
Intervention: Valsalva Maneuver
Description: The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.

Intervention type: DEVICE
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
Study: NCT03112863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bakuchiol
Description: This group will receive bakuchiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinol
Description: This group will receive retinol
Study: NCT01623362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fluoride acidic dentifrice
Description: 550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: conventional dentifrice
Description: 1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neutral pH and low-fluoride dentifrice
Description: 500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
Study: NCT03143920

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy-
Description: Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
Study: NCT01757886

Intervention type: OTHER
Intervention: Biomarkers to analyze both intracoronary thrombi as blood
Study: NCT01348789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go (Mē)
Description: Treatment with Hair2Go (Mē) three times every 2-4 days
Study: NCT01493635

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: analgesic ladder
Description: Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analgesic ladder
Description: Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
Study: NCT02289963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
Study: NCT02108262

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study: NCT02289963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT02038621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study: NCT04684199

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02038621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Capecitabine
Description: Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin and Capecitabine
Description: Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
Study: NCT02105103

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek® Insight Insulin Pump
Description: A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
Study: NCT04029272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg tid for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tid for 12 weeks
Study: NCT03533166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 0.03% Chlorhexidine + 0.05% CPC mouth rinse
Study: NCT04029272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 MG
Description: Exenatide injection once weekly for 12 weeks
Study: NCT04005677

Intervention type: DIAGNOSTIC_TEST
Intervention: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.
Description: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.
Description: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
Study: NCT03533166

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mouth rinse
Study: NCT03490487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional antiepileptic drugs
Description: will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional antiepileptic drugs
Description: will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study: NCT04005677

Intervention type: DIAGNOSTIC_TEST
Intervention: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.
Description: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
Study: NCT02937415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath carbon monoxide
Description: Breath carbon monoxide measurement.
Study: NCT03490487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral steroid
Description: will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study: NCT02937415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath carbon monoxide
Description: Breath carbon monoxide measurement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary function tests.
Description: Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests.
Description: Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidative stress and antioxidant status.
Description: Measurement of parameters of oxidative stress and antioxidant status in blood samples.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxidative stress and antioxidant status.
Description: Measurement of parameters of oxidative stress and antioxidant status in blood samples.
Study: NCT02209922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
Study: NCT02142556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of quetiapine XR
Description: The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
Study: NCT02490163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectra Optia
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
Study: NCT01478646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional breathing therapy
Description: duration: 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflectory breathing therapy
Description: duration: 60 minutes.
Study: NCT03200951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus group for epidural block
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion group for epidural block
Description: Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
Study: NCT03376633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working on Womanhood (WOW)
Description: A trauma-informed group counseling and clinical mentoring intervention for young women
Study: NCT02725489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
Study: NCT01245647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, 50mg, once per day for 4 months
Description: Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill, 50mg, once per day for 4 months
Description: Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
Study: NCT02370121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gymnema Sylvestre
Description: Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
Study: NCT01771926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: potatoes
Description: Daily intake of assigned treatment for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: potatoes
Description: Daily intake of assigned treatment for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: other carbohydrate
Description: Daily intake of assigned treatment for 8 weeks
Study: NCT03423771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution
Study: NCT02725489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
Study: NCT02725489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
Study: NCT01532193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreased oxygen concentration
Description: The oxygen concentration is decreased during the in Vitro embryo culture.
Study: NCT00603772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atralin (tretinoin) gel, 0.05%
Description: Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
Study: NCT00126880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX754
Description: apricitabine, 600mg BID or 800mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX754
Description: apricitabine, 600mg BID or 800mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC
Description: 3TC, 150mg BID
Study: NCT03099343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Location-based Tailored Messaging
Description: The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
Study: NCT01695278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
Study: NCT02575066

Intervention type: RADIATION
Group type: OTHER
Intervention: external beam radiotherapy
Description: external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy

Intervention type: DRUG
Group type: OTHER
Intervention: pazopanib
Description: pazopanib QD 800 mg
Study: NCT02239120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optional ASA as comedication
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to ASA
Description: placebo to comparator drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to optional ASA as comedication
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dabigatran etexilate
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 100 mg
Description: active comparator drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: active drug
Study: NCT02213133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (KPT-330)
Description: Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
Study: NCT03682653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: a single dose of Azithromycin will be administered to infants between their 8-27th days of life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single dose of Placebo will be administered to infants between their 8-27th days of life
Study: NCT00433888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
Study: NCT01587989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 15-25 mg orally weekly, Weeks 1-12
Study: NCT03172351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDoF1
Description: extended depth of focus IOL - EDoF1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDoF1
Description: extended depth of focus IOL - EDoF1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofocal
Description: Monofocal IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal
Description: Monofocal IOL